TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04224493

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 20 mg capsules or 10 mg capsules (if creatinine clearance ≥60 mL/minute or \<60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.
Study: NCT01160055

Intervention type: PROCEDURE
Intervention: Middle ear fluid and urine.
Description: Middle ear fluid and urine collection.
Study: NCT03218254

Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate
Description: Titration of MTP for treatment of fatigue

Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate
Description: Titration of MTP for treatment of fatigue

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study: NCT00121303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Study: NCT04224493

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
Study: NCT03766568

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JGG endoscope(R)
Description: The JGG endoscope(R) is attached to the new generation of Heine® otoscopes with a LED light source that allows the inspection of the ostium in the middle meatus and collection of material for bacterial culture for the diagnosis of ABRS in primary care. After local anaesthesiology of the cavum nasi a sample material for cultures can be gained (earliest 10 min after local anaesthesia). The diagnostic procedure poses patients at minimal risk for complications and is of very little and short-termed discomfort.
Study: NCT00121303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Study: NCT01205620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITPR
Description: • Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No intervention
Description: No intervention will be performed in the control group
Study: NCT04892290

Intervention type: OTHER
Intervention: Conservative Treatment for Postdural Puncture Headache
Description: The patients in Group C were given continuous bed rest in the supine position, 3000 mL daily hydration, 6 mg kg-1 aminophylline , 2 g day-1 paracetamol and 65 mg day-1 caffeine as conservative treatment. Topical SGB was applied to patients in Group SGB in addition to conservative treatment.

Intervention type: OTHER
Intervention: Conservative Treatment for Postdural Puncture Headache
Description: The patients in Group C were given continuous bed rest in the supine position, 3000 mL daily hydration, 6 mg kg-1 aminophylline , 2 g day-1 paracetamol and 65 mg day-1 caffeine as conservative treatment. Topical SGB was applied to patients in Group SGB in addition to conservative treatment.
Study: NCT03862690

Intervention type: DRUG
Intervention: BIAsp 30
Description: Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study.
Study: NCT00967512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cenersen
Description: solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin, cytarabine
Description: idarubicin, cytarabine
Study: NCT03644940

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CustomSight
Description: Subpopulation-specific clinical decision support (CDS) system for severe sepsis detection
Study: NCT00967512

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: idarubicin, cytarabine
Description: idarubicin, cytarabine
Study: NCT03665298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: App that helps patients find syringe exchange programs, safe way to dispose of needles, access to naloxone kits and access to free medical care and addiction treatment programs.
Study: NCT02866435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
Study: NCT02787993

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Mult-Symptom management(CBT)
Description: Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
Study: NCT02892461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Description: As same as that in arm descriptions.
Study: NCT01778088

Intervention type: DRUG
Group type: OTHER
Intervention: I-131-CLR1404 Injection
Study: NCT04349306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RASBURICASE SR29142
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study: NCT02018094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
Study: NCT02950259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: One dose of cyclophosphamide 300 mg/m2 IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: One dose of cyclophosphamide 300 mg/m2 IV infusion
Study: NCT01532063

Intervention type: PROCEDURE
Group type: OTHER
Intervention: INTUBATION IN INTENSIVE CARE UNIT
Description: Standard intubation procedure used in Intensive Care Unit
Study: NCT02950259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin 25 mg three times a day for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin 25 mg three times a day for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: One tablet of omeprazole daily for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: One tablet of omeprazole daily for 21 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Daily multivitamin containing 15-30 mg of zinc for 21 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Daily multivitamin containing 15-30 mg of zinc for 21 days.
Study: NCT04241835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) in tablet form at a dose of 800 mg once daily on days 1 and 15 and twice daily on days 5 to 14 of the first 28-day cycle.~Participants may continue tazemetostat treatment at 800 mg twice daily in additional 28-day cycles until progression or unacceptable toxicity.
Study: NCT00966459

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed Tomography
Description: 1 low-dose CT is taken
Study: NCT00846859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline (Champix/Chantix)
Description: 14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for varenicline
Description: 14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)
Study: NCT03643926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Brostrom
Description: Brostrom-Gould lateral ligament ankle reconstruction performed by arthroscopic view

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Brostrom
Description: Brostrom-Gould lateral ligament ankle reconstruction performed by an open approach.
Study: NCT02697513

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: simple infection management protocol
Description: Implementation of a simple management protocol to improve care of patients with acute infection. Implementation will be assisted by a 1.5-day focused training program.
Study: NCT03185455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote (text based) surveillance
Description: Women with hypertensive disorders of pregnancy with access to a cell phone with unlimited text message capabilities will be randomized to either office visit blood pressure checks after discharge or receive a blood pressure cuff and text in blood pressures for two weeks postpartum using a standardized, HIPAA compliant, physician derived automated platform.
Study: NCT04087343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meals plus exercise
Description: Patients will receive 12 weeks of meals on wheels meal delivery consisting of 3 meals per day during the weekdays with 6 frozen meals to cover the weekends.They will also receive an exercise kit on the first visit by the meal delivery driver with 2 tennis balls,2 1-pound hand weights, and one towel.Every week,the driver will give them 3 exercises from the National Institute on Aging's Go4Life Workout-to-Go book,1 exercise from each of 3 categories:strength/endurance, balance, and flexibility. They will be asked to do the 3 exercises every day.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meals only
Description: Patients will receive 12 weeks of an enhanced meals on wheels (MOW) in-person meal delivery consisting of 3 meals per day (1 shelf-stable, 1 hot, and 1 frozen) during the weekdays (Monday through Friday) with 6 frozen meals at the end of the week to cover the weekends.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
Study: NCT02623036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Equivalent dose enalapril
Description: Chronotherapy with enalapril.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Equivalent dose lisinopril
Description: Chronotherapy with lisinopril
Study: NCT04526756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy
Description: Solitaire stent and manual aspiration thrombectomy were performed as the first-line endovascular treatment
Study: NCT00121992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT03628508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Comprehensive exercise program including strengthening, stretching, gait modification etc.
Study: NCT03317275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-Fluoride-PET/MRI
Description: facet joint injection guided by the anatomical localization of causative structures by PET/MRI compared to standard assessment techniques.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Fluoride-PET/MRI
Description: facet joint injection guided by the anatomical localization of causative structures by PET/MRI compared to standard assessment techniques.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: facet injection
Description: facet joint local anesthetic and corticosteroid injection according to the 18F-Fluoride-PET/MRI result or based on current standard clinical practise (MRI and clinical correlation) respectively

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: facet injection
Description: facet joint local anesthetic and corticosteroid injection according to the 18F-Fluoride-PET/MRI result or based on current standard clinical practise (MRI and clinical correlation) respectively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pain assessment by VAS
Description: VAS questionnaire immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pain assessment by VAS
Description: VAS questionnaire immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
Study: NCT01232894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 µg once-daily via single-dose dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-acting beta2-agonist
Description: Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily
Study: NCT03998475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition preparation intervention
Description: Young adult participants and parents will complete transition preparation sessions that include meeting with a health behavior coach for in-person sessions and review of materials sent electronically between study visits.
Study: NCT01994226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose colchicine
Description: Route of Administration: Tablet - Oral Use~Dose: 500 mcg (one tablet) every eight hours for four days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 750 mg/250 mg
Description: Route of Administration: Tablet - Oral Use~Dose: Single initial dose of 750 mg (three tablets) followed by 250 mg (one tablet) every eight hours for up to seven days
Study: NCT01833767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Interleukin 2
Description: Cytoxan IV day 1, IL2 IV days 1-5
Study: NCT02325635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Training
Description: Intervention/Training offered to endoscopists only.
Study: NCT02795195

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy (CIRT)
Description: Four dose levels (54GyE, 57GyE, 60GyE, 63GyE) are planned within the Phase I part. Daily fraction of 3 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., maximal tolerated dose, is determined or if the treatments to 63 GyE are safely delivered, the recommended dose (or 63 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the gross tumor volume plus 3\~5mm.
Study: NCT01914705

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Landmark Procedure
Description: Using Landmarks to guide SCVC placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Procedure
Description: Using ultrasound to guide SCVC placement
Study: NCT00198445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac
Description: One drop in study eye every 12 hours for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop in study eye every 12 hours for 14 days
Study: NCT01999634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cma microdialysis catheter placement
Description: the microdialysis catheters are sold by CMA
Study: NCT03174717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music performance
Description: residents of LTC will learn and perform songs with musicians from the community
Study: NCT03661827

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stress Cardiac MRI
Description: Dobutamine and adenosine stress MRI
Study: NCT04229589

Intervention type: OTHER
Intervention: Clinic follow-up
Description: Patients are regularly evaluated to asses the occurrence of syncopal relapses
Study: NCT02843373

Intervention type: DEVICE
Intervention: TMS
Study: NCT02866435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium phosphate
Description: Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium phosphate
Description: Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.
Study: NCT03752385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reducing smartphone screen time
Description: Cutting average smartphone screen time in half. Sleeping without smartphone in bedroom. Establishing a bedtime to stop smartphone screen time.
Study: NCT00676533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipro XR (Ciprofloxacin, BAYQ3939)
Description: 3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days.
Study: NCT01909778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: single oral doses
Study: NCT01830842

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine polacrilex
Description: nonsmokers will be measured following nicotine administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nonsmokers will be measured following placebo administration

Intervention type: OTHER
Group type: OTHER
Intervention: satiety
Description: smokers will be measured in a smoking satiated condition

Intervention type: OTHER
Group type: OTHER
Intervention: abstinence
Description: smokers will be measured following 24-hours of smoking abstinence
Study: NCT01935869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle

Intervention type: DRUG
Group type: OTHER
Intervention: Petrolatum ointment
Study: NCT04143555

Intervention type: PROCEDURE
Intervention: endoscopic submucosal injection of indocyanine green before laparoscopic gastrectomy
Description: Indocyanine green was injected under endoscope within 24 hours before operation. Four points(0.5ml/point,1.25mg/ml) were evenly injected in four quadrants at the edge of the tumor. The injection method was direct submucosal injection and 0.5ml saline + 0.5ml indocyanine green solution + 0.5ml saline (sandwich method). The imaging effect was evaluated by indocyanine green fluorescence imaging system during the operation. The effect was divided into grade0 and Grade1. Grade1: The imaging of the tumor and the corresponding lymphatic drainage area in the injection area both were ideal. Grade 0: not up to grade 1, classified into tumor body and drainage area without imaging, only tumor body imaging, and even though tumor body and regional lymph drainage area imaging, the contrast agent in the gastric wall was too diffuse or even overflowing, which seriously interfered with the observation of lymph drainage area imaging.
Study: NCT05490459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
Description: Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
Study: NCT03612258

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging
Description: Functional Magnetic Resonance Imaging scans will be completed to assess neural responses to painful, non-painful sensory, and emotion-eliciting stimuli.
Study: NCT02564848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy without sentinel node biopsy
Description: Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
Study: NCT00407745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)